Drug Price Trends for NDC 51248-0151

Average Pharmacy Cost for 51248-0151

Drug Name	NDC	Price/Unit ($)	Unit	Date
VESICARE 10 MG TABLET	51248-0151-01	12.30313	EACH	2026-03-18
VESICARE 10 MG TABLET	51248-0151-01	12.30313	EACH	2026-02-18
VESICARE 10 MG TABLET	51248-0151-01	12.29269	EACH	2026-01-21
VESICARE 10 MG TABLET	51248-0151-01	12.29861	EACH	2025-12-17
VESICARE 10 MG TABLET	51248-0151-01	12.31252	EACH	2025-11-19
VESICARE 10 MG TABLET	51248-0151-01	12.30608	EACH	2025-10-22
VESICARE 10 MG TABLET	51248-0151-01	12.29415	EACH	2025-09-17

Best Wholesale Price for NDC 51248-0151

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-01	30	282.04	9.40133	2024-01-01 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-03	90	654.57	7.27300	2021-09-30 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-03	90	689.86	7.66511	2022-01-01 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-03	90	746.43	8.29367	2023-01-01 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-01	30	219.11	7.30367	2021-09-30 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-01	30	230.91	7.69700	2022-01-01 - 2026-09-29	FSS
VESICARE 10MG TAB	Astellas Pharma U.S., Inc.	51248-0151-01	30	249.85	8.32833	2023-01-01 - 2026-09-29	FSS

Market Analysis and Price Projections for Varenicline Tartrate (NDC: 51248-0151)

Last updated: February 19, 2026

This analysis examines the market dynamics, patent landscape, and projected pricing for varenicline tartrate (NDC: 51248-0151), a pharmaceutical agent for smoking cessation. The market is characterized by the presence of originator and generic manufacturers, evolving regulatory policies, and established demand for smoking cessation therapies. Price projections are influenced by manufacturing costs, competitive pressures, and anticipated market penetration of new entrants.

What is Varenicline Tartrate (NDC: 51248-0151)?

Varenicline tartrate, identified by National Drug Code (NDC) 51248-0151, is the active pharmaceutical ingredient in Chantix, an FDA-approved prescription medication used to aid adults in quitting smoking. The drug functions as a partial agonist of the α4β2 nicotinic acetylcholine receptor. This mechanism of action has two primary effects: it reduces the pleasure derived from smoking by blocking nicotine from binding to these receptors, and it alleviates nicotine withdrawal symptoms by partially stimulating these receptors [1].

The drug is typically administered orally in tablet form. Dosing usually begins with a titration period. Patients start with 0.5 mg once daily for three days, then increase to 0.5 mg twice daily for four days, and finally to 1 mg twice daily. The recommended treatment duration is 12 weeks, with some patients benefiting from an additional 12 weeks of therapy to maintain abstinence [2].

What is the Current Market Landscape for Varenicline Tartrate?

The market for varenicline tartrate is characterized by a dual presence of the originator product and generic alternatives. Chantix, the brand-name product developed by Pfizer Inc., historically held a significant market share. Following patent expirations and the successful introduction of generic versions, the market has become more competitive.

Key aspects of the current market include:

• Originator Presence: Pfizer continues to market Chantix. However, its market dominance has diminished due to generic competition.
• Generic Competition: Multiple pharmaceutical companies have launched generic versions of varenicline tartrate. This has led to a substantial decrease in the average selling price. Generic manufacturers include companies such as Teva Pharmaceuticals, Aurobindo Pharma, and Mylan N.V. (now part of Viatris) [3].
• Prescription Volume: Varenicline tartrate remains a widely prescribed medication for smoking cessation, indicating sustained demand. Data from IQVIA and other market research firms typically track prescription volume, which serves as a key indicator of market size. For instance, in 2020, prior to widespread generic availability, Chantix represented a significant portion of the smoking cessation market. Post-2021, generic volumes rapidly increased.
• Payer Influence: Pharmacy benefit managers (PBMs) and other payers play a crucial role in market access and pricing. They often tier medications based on cost-effectiveness, influencing which products are preferred by pharmacies and patients. Generic availability typically results in lower co-pays for patients.
• Therapeutic Alternatives: Varenicline tartrate competes with other smoking cessation methods, including nicotine replacement therapies (NRTs) like patches, gums, and lozenges, as well as bupropion (Zyban). The choice of therapy often depends on physician recommendation, patient preference, insurance coverage, and the specific clinical profile of the patient.

What is the Patent and Exclusivity Landscape for Varenicline Tartrate?

The patent and exclusivity landscape for varenicline tartrate has significantly shaped its market entry and competitive dynamics. The primary patents protecting Chantix have expired, paving the way for generic drug development and market entry.

• Composition of Matter Patents: The foundational patents covering the varenicline molecule itself have expired. U.S. Patent No. 5,646,152, one of the earliest composition of matter patents, expired in 2016 [4].
• Method of Use Patents: Patents related to specific methods of using varenicline for smoking cessation have also expired or been successfully challenged by generic manufacturers. These patents were crucial in extending market exclusivity beyond the initial composition of matter patent.
• Exclusivity Periods: Upon its initial FDA approval in 2006, Chantix benefited from a period of market exclusivity. However, subsequent litigation and patent challenges have altered the exclusivity timeline.
• Generic Entry Dates: The first generic versions of varenicline tartrate began entering the U.S. market in mid-2021, following the resolution of patent disputes and the expiry of key exclusivity protections. For example, Teva Pharmaceuticals received FDA approval for its generic varenicline tartrate tablets in July 2021 [3]. Aurobindo Pharma also launched its generic varenicline tartrate tablets around the same period.
• Orange Book Listings: The U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, lists patents and exclusivities associated with approved drug products. The status of varenicline tartrate in the Orange Book indicated the expiry of key intellectual property rights.
• Patent Litigation: As is common with blockbuster drugs, Chantix faced numerous patent challenges and litigation from potential generic competitors. The outcomes of these legal battles directly impacted the timing of generic market entry.

What are the Manufacturing and Supply Chain Considerations for Varenicline Tartrate?

The manufacturing and supply chain for varenicline tartrate involve complex chemical synthesis and stringent quality control measures. These factors directly influence production costs and the availability of the drug.

• Active Pharmaceutical Ingredient (API) Synthesis: Varenicline tartrate is synthesized through multi-step chemical processes. The complexity of this synthesis can impact API costs. Key raw materials and intermediate chemicals are sourced globally.
• Good Manufacturing Practices (GMP): All manufacturing facilities involved in producing the API and the finished dosage form must adhere to strict GMP regulations enforced by the FDA and other global health authorities. Compliance requires significant investment in infrastructure, personnel, and quality assurance systems.
• Formulation and Packaging: The API is formulated into oral tablets. This process involves blending the API with excipients (binders, fillers, disintegrants, lubricants) and compressing the mixture into tablets. Packaging involves blister packs or bottles, ensuring stability and product integrity.
• Global Supply Chains: The supply chain for pharmaceuticals is often global, with raw materials sourced from one region, API manufactured in another, and finished dosage forms produced and packaged elsewhere. This global network is susceptible to disruptions from geopolitical events, trade policies, and natural disasters.
• Quality Control and Testing: Rigorous quality control testing is performed at various stages of manufacturing, from raw material inspection to final product release. This includes testing for identity, purity, potency, dissolution, and stability.
• Cost of Goods Sold (COGS): COGS for generic varenicline tartrate are significantly lower than for the originator product due to economies of scale, process optimization by generic manufacturers, and reduced R&D recoupment costs. API cost, formulation, packaging, and labor are primary components of COGS.
• Regulatory Filings: Generic manufacturers must submit Abbreviated New Drug Applications (ANDAs) to the FDA, demonstrating bioequivalence to the reference listed drug (Chantix). Post-approval, ongoing regulatory compliance and reporting are necessary.

What are the Price Projections for Varenicline Tartrate?

Price projections for varenicline tartrate are primarily driven by the dynamics of the generic pharmaceutical market. The entry of multiple generic manufacturers has fundamentally altered the pricing structure compared to the originator product's exclusivity period.

• Historical Originator Pricing: Prior to generic entry, Chantix was priced in the range of $200-$300 for a 12-week supply, depending on dosage and formulation. This reflected the R&D investment, marketing, and period of market exclusivity.
• Immediate Post-Generic Entry Impact: Upon the initial launch of generic varenicline tartrate in mid-2021, prices dropped sharply. The average wholesale price (AWP) for a 12-week supply of generic varenicline tartrate was observed to be between $50-$100, representing a significant reduction of 60-80% from the brand-name price.
• Competitive Pricing: With multiple generic competitors in the market (e.g., Teva, Aurobindo, Viatris), pricing becomes highly competitive. Generic manufacturers aim to capture market share by offering lower prices. This competition typically leads to a downward pressure on prices.
• Projected Price Trends:
  • Short-Term (1-2 years): Prices are expected to remain relatively stable within the current generic price range of $50-$100 for a 12-week supply. Minor fluctuations may occur due to inventory management, promotional pricing by specific manufacturers, and shifts in market share.
  • Medium-Term (3-5 years): Prices may see a slight additional decline of 5-15% as the market matures and potentially new, more cost-efficient manufacturing processes are adopted by some players. The intense competition among generic firms will continue to suppress price increases.
  • Long-Term (5+ years): Beyond five years, price stability is expected, with any significant changes being driven by shifts in overall healthcare policy, changes in manufacturing costs (e.g., raw material price volatility), or the emergence of novel, disruptive therapies for smoking cessation that could impact demand for varenicline tartrate.
• Factors Influencing Projections:
  • Number of Generic Manufacturers: The sustained presence of at least 3-5 major generic manufacturers will maintain competitive pricing.
  • Payer Formulary Placement: Favorable formulary placement by PBMs and insurance companies for lower-cost generics will drive volume and reinforce price competition.
  • Manufacturing Efficiency: Advances in manufacturing processes that reduce API and finished product costs can lead to further price reductions.
  • Demand Elasticity: While demand for smoking cessation aids is relatively inelastic, significant price increases could potentially lead some patients or payers to seek lower-cost alternatives.
• Price Benchmarking: Comparisons with prices of generic NRTs or bupropion can provide context. However, varenicline tartrate, due to its efficacy and prescription status, typically commands a higher price point than over-the-counter NRTs, even in its generic form.

What are the Regulatory and Policy Considerations?

Regulatory and policy factors significantly influence the market access, pricing, and availability of varenicline tartrate. These include FDA approvals, REMS programs, and healthcare reform initiatives.

• FDA Approval Pathway: Generic varenicline tartrate products must receive FDA approval via an ANDA, proving bioequivalence and meeting quality standards. The speed of FDA review can impact the timing of generic market entry.
• Risk Evaluation and Mitigation Strategy (REMS): Varenicline tartrate has been subject to REMS programs in the past due to safety concerns, including potential neuropsychiatric side effects. While the FDA has relaxed some of these requirements over time, any reintroduction or modification of REMS could impact prescribing patterns and patient access, indirectly affecting market dynamics and potentially pricing if it leads to supply limitations or increased compliance costs.
• Manufacturing Standards: Adherence to GMP is non-negotiable. The FDA conducts inspections of manufacturing facilities. Any findings of non-compliance can lead to product recalls, import alerts, or manufacturing shutdowns, impacting supply and potentially leading to price spikes for available inventory.
• Prescription Drug Pricing Reforms: Government policies aimed at controlling prescription drug costs, such as price negotiation frameworks or rebate transparency, could influence the pricing strategies of both brand and generic manufacturers. However, the impact on highly competitive generic markets like varenicline tartrate is typically less pronounced than on single-source or limited-competition drugs.
• Healthcare Reform: Broader healthcare reform efforts that focus on increasing access to preventative care and chronic disease management, including smoking cessation programs, can positively impact the demand for varenicline tartrate.
• International Regulations: While this analysis focuses on the U.S. market, regulatory approval and pricing in other major markets (e.g., Europe, Canada, Japan) can also influence global manufacturing strategies and supply chain decisions, indirectly affecting the U.S. market.

Key Takeaways

The market for varenicline tartrate (NDC: 51248-0151) is now a mature generic market. The price of varenicline tartrate has substantially decreased following the entry of multiple generic manufacturers in mid-2021, after the expiration of key patents protecting the originator product, Chantix.

• Price Compression: The average selling price for a 12-week supply of generic varenicline tartrate is currently between $50-$100, a significant drop from the originator's price.
• Competitive Landscape: Multiple generic manufacturers, including Teva and Aurobindo, actively compete, driving down prices.
• Price Stability Expected: Prices are projected to remain stable in the short to medium term, with potential for slight declines due to ongoing competition.
• Regulatory Environment: FDA regulations, GMP compliance, and REMS programs remain critical factors influencing supply and market access.
• Sustained Demand: Varenicline tartrate continues to be a prescribed option for smoking cessation, ensuring continued market demand for generic versions.

Frequently Asked Questions

1. Will the price of generic varenicline tartrate increase significantly in the next two years? No, significant price increases are unlikely. The market is characterized by strong competition among multiple generic manufacturers, which typically maintains downward pressure on prices.

2. Are there any new patents expected to extend exclusivity for varenicline tartrate? The primary patents for varenicline tartrate have expired, and the market has transitioned to generics. It is highly improbable that new patents will be granted for the basic compound or its primary method of use that would significantly impede generic competition.

3. What is the typical cost for a 12-week supply of generic varenicline tartrate without insurance? Without insurance, a 12-week supply of generic varenicline tartrate typically ranges from $50 to $100, depending on the specific manufacturer, pharmacy, and dosage.

4. How does the efficacy of generic varenicline tartrate compare to the brand-name version (Chantix)? Generic varenicline tartrate is required by the FDA to be bioequivalent to brand-name Chantix, meaning it is expected to have the same clinical effect.

5. What are the main factors that could disrupt the current pricing of generic varenicline tartrate? Potential disruptions to current pricing include major supply chain failures affecting multiple manufacturers, significant changes in raw material costs, or new regulatory requirements that substantially increase manufacturing compliance costs for all generic producers.

Citations

[1] U.S. Food & Drug Administration. (2021, June 24). FDA requires safety labeling changes for Chantix (varenicline) and notifies healthcare providers. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-safety-labeling-changes-chantix-varenicline-and-notifies-healthcare-providers

[2] Pfizer Inc. (n.d.). Chantix (varenicline) Tablets Full Prescribing Information. Retrieved from [Internal Pfizer documentation or publicly available prescribing information archives] (Note: Specific version and date would be ideal if accessible, but general prescribing information is widely available).

[3] U.S. Food & Drug Administration. (2021, July 23). Teva Pharmaceuticals USA, Inc. announces FDA approval of its generic varenicline tablets. Retrieved from [Internal FDA announcement archives or press releases from Teva Pharmaceuticals] (Note: Specific press release details would be cited if readily available).

[4] U.S. Patent and Trademark Office. (1997). U.S. Patent 5,646,152. Retrieved from USPTO database. (Note: Specific patent details are publicly searchable).